期刊
PHARMACOPSYCHIATRY
卷 47, 期 3, 页码 81-83出版社
GEORG THIEME VERLAG KG
DOI: 10.1055/s-0034-1367014
关键词
psychosis; hallucinations; mirtazapine; SSRI; Parkinson's disease; Lewy bodies
Introduction: Psychosis in Parkinson disease is a therapeutic challenge. Regular strategies of treatment are aimed at reducing dopamine medication, and if necessary addition of clozapine. Methods: We describe the case of a patient with persistent psychosis. Nocturnal visual hallucinations persisted in spite of reduced dopaminergic medication and sequential treatment with atypical antipsychotic medication (quetiapine and clozapine) in combination with an acetylcholinesterase inhibitor (rivastigmine). After dispensing a dopamine enhancing antide-pressant (mirtazapine), prescribed to improve sleeping, the psychotic symptoms almost immediately disappeared while Parkinsons symptoms declined. Results: One other case about a positive effect of mirtazapine on (auditory) hallucinations in Parkinson has been published. The reason for the reduction of psychosis in Parkinson-related disease could have been the effect of antagonism of serotonin (5HT)-2A and/or antagonism of 5HT-2C leading to dopamine release. Discussion: Therapeutic effects of medication with strong antagonism for 5HT-2A and 5HT-2C, like mirtazapine, mianserine, trazodone and nefazodone, in Parkinson-related diseases should be subject for further research. Serotonin might be associated with psychosis in Parkinson-related disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据